Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
828.42
+3.94 (+0.48%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
577,393
Open
826.57
Bid (Size)
828.50 (1)
Ask (Size)
855.00 (1)
Prev. Close
824.48
Today's Range
822.80 - 830.73
52wk Range
784.96 - 1,211.20
Shares Outstanding
91,779,465
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Assessing Regeneron Pharmaceuticals's Performance Against Competitors In Biotechnology Industry
November 06, 2024
Via
Benzinga
3 Recession-Resistant Stocks: Low Beta, High Margins, Low Debt
November 06, 2024
Check out these three stocks with financial metrics showing recession resistance and underlying business dynamics to back them up.
Via
MarketBeat
Topics
Bankruptcy
Bonds
Economy
Exposures
Debt Markets
Economy
Financial
Performance
YTD
-8.46%
-8.46%
1 Month
-18.44%
-18.44%
3 Month
-26.11%
-26.11%
6 Month
-15.20%
-15.20%
1 Year
+3.98%
+3.98%
More News
Read More
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
November 06, 2024
Via
The Motley Fool
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
November 06, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
This Is What Whales Are Betting On Regeneron Pharmaceuticals
November 04, 2024
Via
Benzinga
Regeneron Earnings Top Views For Biotech Giant
October 31, 2024
Via
Investor's Business Daily
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,800 Today
October 24, 2024
Via
Benzinga
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
November 05, 2024
Via
Benzinga
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
November 04, 2024
Via
Talk Markets
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
November 04, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
November 04, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
A Closer Look at 23 Analyst Recommendations For Regeneron Pharmaceuticals
October 23, 2024
Via
Benzinga
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
October 23, 2024
Via
Benzinga
The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
November 01, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
November 01, 2024
Via
Investor's Business Daily
Market Whales and Their Recent Bets on REGN Options
October 23, 2024
Via
Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
October 31, 2024
Via
Benzinga
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
October 31, 2024
Via
Benzinga
Regeneron Reports Third Quarter 2024 Financial and Operating Results
October 31, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
Via
Benzinga
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss
October 28, 2024
Via
Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
October 28, 2024
Via
The Motley Fool
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
October 25, 2024
Via
Benzinga
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
October 24, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Seagate To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Wednesday
October 23, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.